Oncotelic Therapeutics Leverages 28 Million Scientific Abstracts in AI Platform to Outpace Big Pharma

Artificial intelligence is rapidly becoming the defining infrastructure layer of modern drug development, and clinical-stage oncology company Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself at the center of this shift. The California-based firm announced the successful integration of approximately 28 million scientific abstracts into its proprietary PDAOAI platform, a move that underscores its ambition to out-innovate larger pharmaceutical players.

The global AI in drug-discovery market, valued at approximately $3.25 billion in 2026, is projected to grow at a compound annual growth rate of roughly 26% through 2031, reaching over $10 billion, according to industry data cited by the company. Oncotelic’s PDAOAI platform was designed from the outset to be more than a research accelerator for internal programs, the company stated, and the integration of such a vast dataset positions it as a significant contender in the field.

By feeding the platform with millions of scientific abstracts, Oncotelic aims to enhance its ability to identify novel drug targets and accelerate the development of cancer therapies. The company believes that controlling the most intelligent platforms may ultimately control the industry’s future, a perspective that drives its strategy to leverage AI not just as a tool but as a core asset.

Oncotelic’s approach stands out in a market where Big Pharma often dominates with larger resources. The company’s focus on AI-driven drug discovery could level the playing field, offering a more efficient pathway to bring treatments to patients. The announcement highlights the potential for small biotech firms to compete through technological innovation rather than sheer scale.

For investors, the latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC. The broader implications of Oncotelic’s progress extend beyond the company itself, signaling a shift in how drug discovery is approached across the industry. As AI continues to mature, the ability to harness large datasets effectively may become a key differentiator for biotech firms of all sizes.

Oncotelic’s strategy reflects a growing trend where data integration and AI capabilities are seen as critical to future success in pharmaceuticals. With 28 million abstracts now part of its platform, the company is betting that its technology can uncover insights that larger competitors might miss, potentially leading to breakthroughs in oncology treatments.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oncotelic Therapeutics Leverages 28 Million Scientific Abstracts in AI Platform to Outpace Big Pharma.

The post Oncotelic Therapeutics Leverages 28 Million Scientific Abstracts in AI Platform to Outpace Big Pharma appeared first on citybuzz.